Insilico Medicine

Insilico Medicine is a clinical-stage biotechnology company applying generative AI to every step of drug discovery — connecting biology, chemistry, and clinical trials analysis. Founded in 2014, the company has grown to 7 offices, automated laboratories, and hundreds of employees.

What we do

We use generative AI, deep learning, and genomic analysis to identify novel targets, design new molecules, and prioritize candidates across oncology, fibrosis, CNS, immunology, infectious disease, and aging-related conditions.

Highlights

• 30+ active programs, with multiple AI-designed assets in clinical stages. Learn more about our pipeline here
• Lead anti-fibrotic candidate, rentosertib, advanced to clinical trials
• Our programs typically reach preclinical candidate nomination in just 13 months
• Collaborations with major biopharma partners and leading universities

Links

• 🌐 Website: https://insilico.com
• 💼 Careers: https://insilico.com/careers
• 🌐 Linked In: https://www.linkedin.com/company/in-silico-medicine/